31 results about "Single tumor" patented technology

Here the inventors describe a tumor classifier based on protein expression. Also disclosed is the use of proteomics to construct a highly accurate artificial neural network (ANN)-based classifier for the detection of an individual tumor type, as well as distinguishing between six common tumor types in an unknown primary diagnosis setting. Discriminating sets of proteins are also identified and are used as biomarkers for six carcinomas. A leave-one-out cross validation (LOOCV) method was used to test the ability of the constructed network to predict the single held out sample from each iteration with a maximum predictive accuracy of 87% and an average predictive accuracy of 82% over the range of proteins chosen for its construction.

The invention belongs to the technical field of chip detection and particularly discloses an antibody chip kit for detecting early gastric cancer. The antibody chip kit is characterized in that various gastric cancer marker related antibodies are fixed onto a solid-phase carrier, and the specific antibodies are screened from 35 routine gastric cancer marker related antibodies. The antibody chip kit can detect a plurality of gastric cancer related antigen proteins at the same time, and the detection effect of a combined antibody chip is better than that of single tumor markers.

The invention provides a building method and applications of a living tumor tissue bank. Tumor tissues of a cancerous patient subjected to an operation are transplanted to a part under the renal capsules of SCID (severe combined immunodeficient mice) and survive in the bodies of the mice for passage conservation, so that the living tumor tissue bank is obtained; the living tumor tissue bank means that based on single tumor tissue heterograft, numerous human body tumor tissues are conserved in animal bodies in a living tissue bank form for standby application; the living tumor tissue bank comprises transverse multiple tumors and various subtypes or various development phase of a certain longitudinal tumor. The living tumor tissue bank has multiple applications in the aspects of determining the personalized therapeutic schedule of the cancerous patient subjected to the operation, screening tumor specificities of anti-cancer drugs, and building animal models for human body cancer research.

The invention relates to a method for performing prognosis condition grouping on a hepatocellular carcinoma patient who has single tumor and is about to be subjected to or is already subjected to orthotopic liver transplantation. The method comprises the steps of (1) obtaining a sample from general samples after transhepatic biopsy before transplantation or liver transplantation, and detecting CK19 and GPC3 expression conditions of tumor cells in the hepatocellular carcinoma tissue sample of the patient; (2) detecting and recording a maximum diameter of the tumor of the patient; (3) detecting and recording a serum alpha-fetoprotein level of the patient; and (4) based on a pathological section, observing whether microvascular invasion exists or not. Recurrent risks are scored according to beta coefficients of four factors in COX regression analysis; scores in items are subjected to addition; a recurrent risk group with a total score less than or equal to 4 is determined as a low recurrent risk group; a recurrent risk group with a total score equal to 5-7 is determined as a medium recurrent risk group; and a current risk group with a total score more than or equal to 8 is determined as a high recurrent risk group. Through the method, an effective auxiliary information value can be provided for a doctor and the patient; and tumor recurrence or transfer is closely monitored, so that health conditions can be discovered within the shortest time, the doctor and the patient are effectively prompted, and people are reminded to timely examine body conditions.

The invention discloses a microsatellite instability detection and prediction method, a related site screening method, a model construction method and an application. The site screening method comprises the following steps: i) determining a microsatellite instability predicted value of a candidate microsatellite site in a sample; and / or ii) screening sites or site combinations for microsatellite instability detection by using one or more indicators including the microsatellite instability predicted value of the candidate microsatellite site; wherein the microsatellite instability predicted value is a quantified value of an abundance difference between a major allele type and a minor allele type in the candidate microsatellite site. The method provided by the invention is high in accuracy,and can accurately and stably detect the MSI state only on the basis of a single tumor sample.

The invention discloses a microsatellite instability detection site screening method based on single tumor sample high-throughput sequencing. The method is based on an optimized microsatellite site state mark, and the machine learning techniques are employed for modeling analysis of each microsatellite site; whether each sample is in a microsatellite unstable state or not is detected by utilizingthe percentage that effective sites are judged as microsatellite unstable sites, so the microsatellite instable state is detected only by utilizing tumor sample sequencing data, the stability of a plurality of microsatellite sites can be judged with high precision, and the accurate and stable microsatellite instable state gene detection is realized.

The invention relates to a method and equipment for detecting tumor microsomes, and especially relates to and discloses a method and a detector for detecting tumor microsomes by using laser tweezers and micro fluidics. The detection method comprises the steps that: laser tweezers of different polarizations are generated; dual-beam double laser tweezers are used for focusing, and particles combined with tumor microsome antibodies in a channel of a micro fluidic chip are captured by the tweezers; a sample to be detected is mixed with the particles combined with tumour microsome antibodies; changes of physical parameters of the particles combined with tumor microsome antibodies before and after being mixed with the sample are collected by the detector, and qualification and accurate quantitation of the sample requiring detection can be carried out according to the parameters. The detector comprises a laser system, a nanometer positioning system, a camera system, optical parts, mechanical parts, a data collecting and transmitting system, and automatic controlling and image processing application software. According to the invention, single tumor microsome particle can be detected, and the method and the equipment are characterized in high specificity, simple operation, short detection period, high sensitivity, and good repeatability. Also, with the method and the equipment, blood samples can be re-detected.

The invention belongs to the technical field of copy number variation detection, and discloses a copy number variation and deletion type detection method and computer based on a single tumor sample. The method includes the steps of building a dynamic balancing mechanism of a copy number extension and deletion range, iterating the detection process to constantly correct the benchmark of reading thesegment number, correcting the parameters of statistical test distribution, and objectively detecting significant copy number variation and weakly-significant copy number variation; building a Bayesian inference model, and correctly detecting the copy number variation state and the copy number deletion type. According to the method and the computer, the copy number variation state and the copy number deletion type are correctly detected, and the information of heterozygote deletion and homologous deletion is provided; the comparation quality and the comparation error problem are considered, and the whole genome GC content is reasonably corrected; the dynamic balancing mechanism of the copy number extension and deletion range is built to accurately position the benchmark of the copy numberand accurately detect the variation state of the copy number.

The invention relates to the field of drug efficacy screening, and particularly discloses a tumor in-vitro culture method. The tumor in-vitro culture method includes the steps that tumor tissue samples are collected; the tumor tissue samples are treated, and single tumor cells and macrophages are sorted; the single tumor cells are placed in an environment full of hydrogel and then are screened toobtain tumor stem cells; the tumor stem cells and the macrophages are adopted to build a co-culture model to obtain in-vitro culture tumor samples. In this way, the tumor stem cells with high proliferation and differentiation capabilities can be screened out in vitro, therefore, the tumor stem cells are implanted into the animal body, the tumor formation time can be greatly shortened, the tumor formation rate is increased, and then susceptibility testing is conducted; therefore, the progress of susceptibility testing is speeded up, and time for treating patients is bought.

The invention discloses a diagnosing and indicating method for the non-small cell lung cancer and a bioinstrumentation kit. Multiple tumor markers are jointly applied to diagnosing and indicating of the non-small cell lung cancer, and the specificity and sensitivity are both remarkably higher than those of diagnosing and indicating the non-small cell lung cancer through a single tumor marker. The invention further provides the bioinstrumentation kit based on multiple markers. The kit is convenient to use, good in specificity, high in sensitivity, capable of being used for diagnosing of the non-small cell lung cancer, treating effect evaluation in the treating process and monitoring of the transferring and relapsing after treatment, and very high in clinical application prospect.

The invention discloses a preparation method of an AFP / HBsAg double-targeting Dexosome anti-hepatoma anti-tumor vaccine. A novel double-targeting anti-hepatoma anti-tumor vaccine is prepared by the following steps: by using a recombinant human adenovirus vector as one target of a hepatoma associated antigen AFP gene and combining the characteristics of primary hepatic carcinoma of China, combining a specific antigen HBsAg of hepatoma associated virus as an immune immunotherapy target; importing DC; and extracting Dexosome, wherein the anti-hepatoma immunological effect induced is enhanced. The novel Dexosome anti-tumor vaccine can be combined with an antigen peptide at the same time through MHC-I / II molecules, so that not only can the CD8+cytotoxic T cell be activated, but also the CD4+auxiliary T cell can be activated. The method overcomes the problems in the prior at that the immunological effect induced by a single tumor antigen is weak, DC is complex to prepare and the like and is a preparation method of a novel non-cellular Dexosome anti-hepatoma anti-tumor vaccine.

The invention relates to an inhibitive ability synthesis Notch, a dual-target spot system and a preparation method and application of the dual-target spot system. The inhibitive ability synthesis Notch comprises fusion protein combined by a Notch1 sequence and CSK kinase. The inhibitive ability synthesis Notch is used for obtaining the dual-target spot system, at the same time, two kinds of tumor-associated antigen can be targeted, accuracy of T cells to kill and wound cancer cells is improved, and off-target virulence caused by targeting single tumor-associated antigen is overcome.

The invention discloses a composition and immune cells for enhancing T lymphocyte immunity and application. The composition of the present invention comprises the following components (a) to (d): (a)interleukin-15, a mutant thereof or a functional fragment thereof, or an encoding nucleic acid thereof; (b) interleukin-15 receptor alpha, a mutant or a functional fragment thereof, or an encoding nucleic acid thereof; (c) interleukin-12, a mutant or a functional fragment thereof, or an encoding nucleic acid thereof; and (d) a PD1-CD80 fusion protein, a mutant or a functional fragment thereof, oran encoding nucleic acid thereof. The composition, the immune cells and the method for improving the properties of the T lymphocytes can all excite stronger immune response, and induce tumor specificCD4 and CD8T cells in a higher proportion, so that the defects of tumor immunosuppression and non-ideal clinical effect which are difficult to solve by a single tumor treatment means are expected to be overcome.

The invention discloses a biomarker for diagnosing and predicting breast cancer and a detection kit. Multiple tumor markers are applied in a combined manner to diagnose and predict the breast cancer, and both specificity and sensitivity are obviously higher than those when a single tumor marker is used for diagnosing and predicting the breast cancer. The invention further provides a biological detection kit based on multiple markers. The kit is convenient to use, high in specificity and sensitivity, suitable for being used for diagnosis of the breast cancer, capable of realizing curative effect evaluation and monitoring of post-treatment metastasis and recurrence in the process of treatment and quite wide in clinical application prospect.

The invention discloses a tumor marker and a combined detection method thereof in blood. The tumor marker comprises MFG-E8, CA153 and CEA. The combined detection method comprises the steps of the serum level detection of MFG-E8, CA153 and CEA, the setting of critical value, statistical analysis, comparison of three indexes detection of the serum level of MFG-E8, CA153 and CEA and comparison of positive rate, and combined detection of the serum level of MFG-E8, CA153 and CEA. Ar present most marker has a high sensitivity and low selectivity, the marker with a high selectivity has a low sensitivity, therefore the present markers cannot be used for an early diagnosis and differential diagnosis of tumor in an optimal manner. The tumor marker and the combined detection method thereof in blood compensate the deficiency that a single tumor marker suffers from either insufficient sensitivity or insufficient selectivity in a clinical test. The selection of MFG-E8, CA153 and CEA for the combined detection can improve the sensitivity, selectivity and accuracy of the detection.

The invention discloses a VX2 rabbit liver transplantation tumor model. A construction method of the VX2 rabbit liver transplantation tumor model comprises the steps as follows: firstly, an anesthetic for intramuscular injection is prepared, the concentration of the anesthetic is 3% pentobarbital sodium, and the dosage is 1 mL / kg; then the VX2 tumor block for intramuscular injection is processed into a tumor block with the size of 1*1*1 mm<3>, the tumor block is inoculated into the body of a young rabbit in the anesthetic state for tumor formation, and the tumor formation parts are rabbit thigh muscle parts on the two sides of the young rabbit; and finally, separated VX2 tumor tissue is rapidly stored in PBS (Phosphate Buffer Solution) at 4 DEG C, muscular tissues around the tumor are removed by using a cell operation table, the tumor block is cut into 1*1*1 mm<3>, and the tumor block is transplanted into the liver of a healthy adult rabbit for planting. The VX2 rabbit liver transplantation tumor model is high in tumor formation rate, a formed tumor is a single tumor generally, the probability of abdominal cavity implantation metastasis and abdominal cavity infection is low, and follow-up experimental research is facilitated.

The invention provides a circulating tumor cell metabolic activity intelligent detection system based on 5G and a block chain and application, and belongs to the technical field of tumor cell detection equipment.The circulating tumor cell metabolic activity intelligent detection system comprises a box body, a containing groove is formed in the upper end of the box body, and a second fixing plate and a third fixing plate are fixedly connected between the left inner wall and the right inner wall of the containing groove; a first fixing plate is fixedly connected to the upper end of the box body, a detection reagent tank is arranged between the left inner wall and the right inner wall of the containing groove and used for containing a detection sample and a reaction reagent, a mixing tank is arranged on the lower inner wall of the containing groove and used for evenly stirring and mixing the detection sample and the reaction reagent, and a leukocyte separation tank is arranged on the rear side of the mixing tank. The problems that an existing tumor cell detection device is based on an electron microscope and a fluorescent targeting reagent, operation is complex, a large amount of time is consumed, high operation capacity is needed for operators, the device is large in size and inconvenient to carry, and single tumor cells cannot be captured and counted are solved.

The use of genomic tests shows variability between the primary tumor and the metastases in most circumstances referred to as tumor heterogeneity. Since it is unduly invasive and difficult to obtain samples from the primary and metastatic tumors within a patient, a need exists for a method of testing chemotherapeutic effectiveness in a patient that is applicable to both primary tumor and metastases. Provided are methods of using the MiCK assay to determine the most effective drug candidate(s) for an individual patient by testing a single tumor site. In a further embodiment, the kinetic unit (KU) value obtained by analysis of cancer cells from a tumor site in an individual patient in the presence of a drug candidate is within two standard deviations of the KU value obtained by analysis of a different tumor site in the patient in the presence of the same drug candidate.

The invention relates to the technical field of microsatellite site detection, in particular to a method and system for detecting the instability state of a microsatellite; and the method comprises the following steps: carrying out DNA extraction, fragmentation treatment, terminal repair and joint connection on a cancerous tissue sample; carrying out amplification, hybridization, capture, PCR amplification and purification to obtain a sequencing library; and obtaining targeted capture sequencing data of a tumor tissue sample through second-generation computer sequencing, and carrying out information analysis related to microsatellite instability state detection according to an MSI model. Compared with the prior art, the genetic information of the tumor tissue of the testee is obtained by adopting the current mature next-generation sequencing technology, single tumor tissue analysis can be carried out, dependence on a control sample is avoided, the limitation of microsatellite detectionis broken through, the method can be suitable for multiple gene combinations, an MSI site probe does not need to be specially designed, and the applicability is high; moreover, the detection cost canbe saved, the method is efficient, systematic, economic, simple and convenient, and the detection sensitivity is improved.

The present invention relates to the technical field of detection of microsatellite sites, in particular to a method and system for detecting instability of microsatellites. DNA is extracted from cancerous tissue samples, fragmented, end repaired, and jointed; and then amplified , hybridization, capture, PCR amplification, and purification to obtain a sequencing library; obtain targeted capture sequencing data of tumor tissue samples through second-generation sequencing, and analyze information related to microsatellite instability detection based on the MSI model. Compared with the existing technology, the present invention adopts the current mature next-generation sequencing technology to obtain the genetic information of the tumor tissue of the test subject, can analyze a single tumor tissue, does not rely on control samples, breaks the limitation of microsatellite detection, and is applicable Based on the combination of multiple genes, there is no need to specially design MSI site probes, the applicability is strong, and the detection cost can be saved. It is efficient, systematic, economical and simple, and improves the sensitivity of detection.

The use of genomic tests shows variability between the primary tumor and the metastases in most circumstances referred to as tumor heterogeneity. Since it is unduly invasive and difficult to obtain samples from the primary and metastatic tumors within a patient, a need exists for a method of testing chemotherapeutic effectiveness in a patient that is applicable to both primary tumor and metastases. Provided are methods of using the MiCK assay to determine the most effective drug candidate(s) for an individual patient by testing a single tumor site. In a further embodiment, the kinetic unit (KU) value obtained by analysis of cancer cells from a tumor site in an individual patient in the presence of a drug candidate is within two standard deviations of the KU value obtained by analysis of a different tumor site in the patient in the presence of the same drug candidate.

The invention belongs to the technical field of chip detection and particularly discloses an antibody chip kit for detecting early gastric cancer. The antibody chip kit is characterized in that various gastric cancer marker related antibodies are fixed onto a solid-phase carrier, and the specific antibodies are screened from 35 routine gastric cancer marker related antibodies. The antibody chip kit can detect a plurality of gastric cancer related antigen proteins at the same time, and the detection effect of a combined antibody chip is better than that of single tumor markers.

The present invention provides a tumor cell content assessment method, device, system and computer-readable medium capable of improving the accuracy of tumor cell content assessment, wherein the tumor cell content assessment method includes the following steps: obtaining one by one the tumor cells that meet the predetermined mutation condition The average sample mutation frequency and control mutation frequency of the mutation site, and calculate the content of individual tumor cells corresponding to the mutation site; once the content of all individual tumor cells corresponding to all mutation sites that meet the predetermined mutation conditions are obtained, the calculating the content of all individual tumor cells to obtain the content of tumor cells in the test sample; evaluating the calculated content of tumor cells in the test sample according to a predetermined evaluation rule to obtain the content of tumor cells in the test sample after evaluation.

The invention relates to an inhibitory synthetic Notch and dual-target system and its preparation method and application, which comprises a fusion protein combining Notch1 sequence and CSK kinase. Using the inhibitory synthetic Notch to obtain a dual-target system can simultaneously target two tumor-associated antigens, improve the accuracy of T cells in killing tumor cells, and effectively overcome the off-target toxicity caused by targeting a single tumor-associated antigen.

The invention discloses a chromosome aneuploid detection method and device based on NGS, a medium and equipment, and relates to the technical field of biomedicine. Comprising the following steps: receiving NGS sequencing data of tumor tissues and normal tissues; preprocessing the NGS sequencing data to obtain an intermediate data file; performing consistency evaluation on the gender and embryonic line SNP by utilizing the intermediate data file; acquiring coverage depth information and SNP genotype information on a to-be-detected sample genome by utilizing the intermediate data file; detecting the purity, ploidy and SCNV fragments of the tumor sample; calculating the SCNV of the chromosome arm level of each tumor sample according to the single tumor sample and the prepared SCNV database; and calculating a final chromosome aneuploid score of each tumor sample based on the SCNV of the sample chromosome arm level. The device, the medium and the equipment are all based on the method. According to the invention, the accuracy of tumor chromosome aneuploid detection is improved.

The invention discloses a method, a system and a probe set for determining a site combination for detecting an unstable state of a microsatellite. The method is a method which uses a single tumor sample and is based on a next-generation sequencing technology, and comprises the following steps: (1) preliminarily screening to obtain a candidate site set consisting of a plurality of microsatellite sites; and (2) calculating the contribution degree of each microsatellite locus in the candidate locus set to the MSI state, sorting the microsatellite loci in the candidate locus set according to the contribution degree, forming a screening locus set by using the microsatellite loci with the top n ranks, and calculating the sample MSI scores of the two groups of samples MSI-H and MSS by using the screening locus set, and obtaining a required site combination according to the sample score. The site combination disclosed by the invention not only can improve the accuracy and sensitivity of microsatellite state detection, but also greatly reduces the detection cost of a single sample process.